Does celiac disease cause secondary exocrine pancreatic insufficiency that can improve with a gluten-free diet?

Celiac disease is a well-documented cause of secondary exocrine pancreatic insufficiency (EPI). Research confirms that this condition is characterized by a functional impairment of the pancreas rather than structural damage, primarily driven by the underlying intestinal enteropathy.

Mechanistic basis of secondary EPI

The development of EPI in celiac disease is linked to the destruction of the duodenal and jejunal mucosa (villous atrophy).

• Hormonal signaling impairment: The intestinal damage impairs enteroendocrine cells, reducing the release of secretin and cholecystokinin (CCK). These hormones are essential for signaling the pancreas to secrete bicarbonate and digestive enzymes, respectively.
• Functional deficit: In the absence of these hormonal triggers, the structurally healthy pancreas fails to receive the necessary signals to release enzymes, leading to a state of secondary pancreatic insufficiency.

Clinical findings and fecal elastase

Fecal elastase-1 (FE-1) is the standard non-invasive biomarker used to identify this insufficiency in celiac patients.

• Prevalence of low FE-1: Approximately 28% to 30% of newly diagnosed, untreated celiac patients exhibit low FE-1 levels (typically defined as <200 μg/g). In study cohorts, mean FE-1 levels in untreated patients have been measured as low as 141.6 μg/g.
• Correlation with damage: There is an inverse relationship between the severity of mucosal damage (villous atrophy) and FE-1 levels; more extensive enteropathy typically results in lower fecal elastase.

Impact of treatment

Because the pancreatic insufficiency is secondary to the intestinal damage, treating the enteropathy directly addresses the cause of low enzyme levels.

• Recovery on a gluten-free diet (GFD): Clinical evidence shows that as the intestinal mucosa heals on a GFD, the production of secretin and CCK is restored.
• Normalization rates: Studies indicate that approximately 86% of celiac patients with initial low FE-1 levels see these levels normalize within 3 to 6 months of strict adherence to a GFD. Persistent low FE-1 is usually reserved for cases of non-responsive celiac disease or rare concurrent primary pancreatic disease.

Bottom line

Celiac disease causes secondary exocrine pancreatic insufficiency by disrupting the hormonal signals (secretin and CCK) needed for pancreatic stimulation. This frequently manifests as low fecal elastase, which typically resolves as the intestinal lining heals on a gluten-free diet.